Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10344222 | 0.91 | KMT2A (0.51) | LMNAKMT2AKDM4EMEN1CRHBP | |
| SCHEMBL819332 | 0.87 | LMNA (0.74) | LMNAKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL29418226 | 0.87 | LMNA (0.74) | LMNAKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL6890528 | 0.86 | LMNA (0.59) | LMNAKMT2AKDM4EMEN1CRHBP | |
| SCHEMBL14151440 | 0.85 | KMT2A (0.64) | LMNAKMT2AKDM4EMEN1CRHBP | |
| SCHEMBL9410965 | 0.84 | CYP3A4 (0.61) | LMNAKMT2AKDM4EMEN1CRHBP | |
| SCHEMBL6895062 | 0.84 | ALDH1A1 (0.55) | LMNAKMT2AL3MBTL1TDP1HPGD | |
| SCHEMBL16675180 | 0.83 | LMNA (0.69) | LMNAKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL13960012 | 0.83 | KDM4E (0.47) | LMNAKMT2AKDM4EMEN1CRHBP | |
| SCHEMBL16359929 | 0.83 | KMT2A (0.46) | LMNAKMT2AKDM4EMEN1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421441-A1 | CONCRETE COLORING COMPOSITIONS AND METHODS | SWIMC LLC (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2147075-B1 | WEAK ACID BASED CONCRETE STAIN | SWIMC LLC (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2365946-B1 | CONCRETE COLORING COMPOSITIONS AND METHODS | VALSPAR SOURCING INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2571090-B9 | NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-9553333-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-01-24 | — | — | US | disclosed |
| US-9472828-B2 | Nonaqueous electrolyte solution, electricity storage device using same, and trifluoromethylbenzene compound | UBE INDUSTRIES, LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| EP-2571090-B1 | NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20150044554-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| CN-102209695-B | Concrete coloring compositions and methods | VALSPAR CORP | 2014-12-24 | — | — | CN | disclosed |
| CN-101842457-B | Weak acid based concrete stain | VALSPAR CORP | 2014-09-03 | — | — | CN | disclosed |
| WO-2008140694-A1 | WEAK ACID BASED CONCRETE STAIN | VALSPAR CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080276387-A1 | Weak Acid Based Concrete Stain | SWIMC LLC | 2008-11-13 | — | — | US | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-0760359-B1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL CO (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-5714627-A | REACTING A DIALKYL CARBONATE WITH AN AROMATIC CARBOXYLIC ACID ARYL ESTER IN THE PRESENCE OF A CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-02-03 | — | — | US | disclosed |
| EP-0760359-A1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | LMNA 2043/4885KMT2A 3040/4885KDM4E 1406/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | LMNA 3199/4885KMT2A 3947/4885KDM4E 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.